Chargement en cours...
A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
BACKGROUND: Molecular targeted therapies were found to be efficacious and safer in the treatment of metastatic renal cell carcinoma (mRCC). Sorafenib is the first target agent (TA) to report a benefit in this disease and has largely established a prominent role in progression-free survival (PFS). Ho...
Enregistré dans:
| Publié dans: | Medicine (Baltimore) |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Wolters Kluwer Health
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6344165/ https://ncbi.nlm.nih.gov/pubmed/30608388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000013779 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|